TMPRSS2 and prostate cancer: T:E fusion-positive prostate cancer was obtained by considering fusions of exon 1 of TMPRSS2 to exon 4 or exon 5 of ERG (n = 86) because exon 4 or exon 5 of ERG are the most abundant breaking sites, generating T:E fusions [10].